Journal of International Oncology››2013,Vol. 40››Issue (2): 123-126.

Previous ArticlesNext Articles

Application ofpemetrexedfor the treatment of non-small-cell lung cancer

LI Jun, XU Xiang-Ying

  1. Department of Radiation Oncology ,the Thi rd Affiliated Hospital ,Harbin Medical University,Harbin 150081,China
  • Online:2013-02-08Published:2013-01-25
  • Contact:Corresponding author: Xu Xing-ying, E-mail: xuxxyy@sohu.com E-mail:xuxxyy@sohu.com

Abstract:Pemetrexed is a novel antifolate which is approved in the USA and Europe for the treatment of non-small-cell lung cancer (NSCLC). Researches reveal that pemetrexed enhances radiation-induced cell inactivation. A series of clinical trials of pemetrexed combined with radiotherapy for NSCLC also demonstrated that pemetrexed provides similar ef?cacy with lower toxicity and better tolerability than other third-generation chemotherapy drugs.

Key words:Carcinoma, non-samll-cell lung,Radiotherapy,Pemetrexed